Eaton Vance Management’s Xenon Pharmaceuticals XENE Stock Holding History

Eaton Vance Management’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-2,500	Closed	-$78K	–	2740
2021 Q4	$78K	Hold	2,500	–	–	﹤0.01%	1931
2021 Q3	$38K	Hold	2,500	–	–	﹤0.01%	1565
2021 Q2	$47K	Hold	2,500	–	–	﹤0.01%	2178
2021 Q1	$45K	Buy	+2,500	New	+$42.4K	﹤0.01%	1823

Other funds holding XENE

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Eaton Vance Management's XENE Position: Q1 2022 in Review

Eaton Vance Management sold out of Xenon Pharmaceuticals (XENE) in Q1 2022, closing a stake of 2,500 shares — an estimated $78K sold.

Eaton Vance Management first reported a position in XENE in Q1 2021 and held it in 4 quarters. The position peaked at $78K in Q4 2021. 133 funds tracked by Wall St. Rank hold XENE as of Q1 2022.

Eaton Vance Management reported no remaining Xenon Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Eaton Vance Management sold 2,500 Xenon Pharmaceuticals shares in Q1 2022, an estimated $78K.
Eaton Vance Management first reported a position in Xenon Pharmaceuticals in Q1 2021 and held it in 4 quarters.
Eaton Vance Management's Xenon Pharmaceuticals position peaked at $78K in Q4 2021.
133 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2022.

Based on Eaton Vance Management's 13F filing for Q1 2022, filed 16 May 2022.